AtoCap Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 5


  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $998K

  • Investors
  • 3

AtoCap General Information


Developer of a microencapsulation technology designed to deliver generic antibiotics for urinary tract infection with chemotherapeutics into a multi-layered capsule. The company's technology fabricates encapsulated products for controlled drug delivery for immunocompromised patients, pregnant women, and multiple sclerosis patients who are at a high risk of contracting UTI, enabling healthcare organizations to prepare a wide range of encapsulated structured drugs via a clean, efficient, one-step route.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • The Network Building
  • 97 Tottenham Court Road
  • London W1T 4TP
  • England, United Kingdom
+44 07703 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AtoCap Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 03-Nov-2020 $998K 00.000 00.000 Completed Generating Revenue
5. Secondary Transaction - Private 01-Jan-2017 00000 Completed Generating Revenue
4. Early Stage VC 02-Feb-2017 00000 00000 00.000 Completed Generating Revenue
3. Debt - General 01-Jan-2013 Completed Generating Revenue
2. Early Stage VC 17-Mar-2011 Completed Generating Revenue
1. Spin-Off 01-Jan-2011 Completed Startup
To view AtoCap’s complete valuation and funding history, request access »

AtoCap Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 10,119 $0.129772 $77.86 $77.86 1x $77.86 29.05%
To view AtoCap’s complete cap table history, request access »

AtoCap Executive Team (8)

Name Title Board Seat Contact Info
Jennifer Rohn Ph.D Chief Scientific Officer
William Bonfield Ph.D Co-Founder & Co-Chairman
Eleanor Stride Co-Founder & Board Member
Mohan Edirisinghe Co-Founder & Board Member
Ann Savell Chief Executive Officer, Chief Financial Officer & Chief Operating Officer
You’re viewing 5 of 8 executive team members. Get the full list »

AtoCap Board Members (9)

Name Representing Role Since
Alexander Pitt Mustard Seed Impact Board Member 000 0000
Andrew Lynn Ph.D Self Co-Chairman 000 0000
Cristina Diaz AtoCap Board Member 000 0000
Eleanor Stride AtoCap Co-Founder & Board Member 000 0000
Mohan Edirisinghe AtoCap Co-Founder & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

AtoCap Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AtoCap Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mustard Seed Impact Venture Capital Minority 000 0000 000000 0
Oxford Innovation Finance Angel Group Minority 000 0000 000000 0
UCL Business University Minority 000 0000 000000 0
To view AtoCap’s complete investors history, request access »